Pharmaceutical Companies' New mRNA Replicon "Vaccines" | The Next Injectable Bioweapon Readies Itself by Big Pharma | Already Endorsed for Distribution in Japan | Refuse to Participate
Japan has made a groundbreaking move in the global fight against COVID-19, becoming the first country to approve a self-amplifying mRNA (replicon) vaccine for human use. The vaccine, known as "KostaiveTM for Intramuscular Injection" (aka "ARCT-154"), is set to roll out as early as next month as part of Japan's October covid-19 vaccination campaign.
The approval of this new vaccine technology, which is still emerging and undergoing evaluations for safety and efficacy, has raised concerns and sparked a vocal protest movement in Japan. The potential risks associated with replicon vaccines include overexpression or prolonged immune stimulation, autoimmune reactions, and the production of truncated or modified proteins.
The use of self-replicating genetically modified organism (GMO) technology as vaccines lends itself to the production of bioweapons, making the safety and efficacy of these vaccines a matter of global concern. Replicon vaccines, also known as sa-mRNA vaccines, are a new experimental vaccine technology.
While the mRNA "vaccine" platforms, including replicon vaccines, are inherently unsafe and have not been subjected to long-term safety studies or experimental studies on genotoxicity, mutagenicity, genomic integration, or genomic instability, the vaccine has already been updated to protect against the JN.1 lineage of Omicron subvariants.
The alphavirus RNA polymerase in replicon vaccines has low fidelity, meaning that in every replication cycle, there is likely to be errors (mutations) in the copied sequences, leading to aberrant proteins being produced. This is a concern, as intracellular translation of synthetic mRNA molecules in replicon vaccines can have serious health consequences.
One "hepatic event" was reported in the Phase III trial of the vaccine, which Science says "will bear watching as it rolls out into a larger population." Additionally, self-replicating replicon vaccines could potentially transmit or shed the "vaccine" product to others through bodily fluids, gases, and contact, raising ethical questions about potential unintended transmission to people who have not consented to receive the vaccine.
Despite these concerns, the vaccine has already been updated and is set to be rolled out in Japan. The sixth edition of the International Covid Summit will be held in Tokyo at the end of September, where doctors and health professionals from around the world will gather to discuss the ongoing threat of the replicon vaccine and other COVID-19 related topics.
As the world continues to grapple with the pandemic, the approval and rollout of self-amplifying mRNA vaccines like ARCT-154 highlight the need for continued vigilance, scientific scrutiny, and open public debate about the potential health effects of this new vaccine platform. The risks and concerns associated with replicon vaccines require careful monitoring and further research to ensure the safety and wellbeing of those receiving the vaccine.
- The approval of the self-amplifying mRNA vaccine, ARCT-154, in Japan, a new experimental vaccine technology, has sparked concerns about its safety and efficacy.
- The potential risks associated with replicon vaccines, such as overexpression or prolonged immune stimulation, autoimmune reactions, and the production of truncated or modified proteins, have led to a vocal protest movement in Japan.
- Replicon vaccines, like ARCT-154, are inherently unsafe and have not been subjected to long-term safety studies or experimental studies on genotoxicity, mutagenicity, genomic integration, or genomic instability.
- Despite these concerns, the sixth edition of the International Covid Summit will be held in Tokyo at the end of September, where doctors and health professionals from around the world will discuss the ongoing threat of replicon vaccines and other COVID-19 related topics.
- The use of self-replicating genetically modified organism (GMO) technology as vaccines, like replicon vaccines, lends itself to the production of bioweapons, making the safety and efficacy of these vaccines a matter of global concern.
